{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,3]],"date-time":"2025-09-03T12:22:49Z","timestamp":1756902169319,"version":"3.44.0"},"reference-count":58,"publisher":"The Pediatric Pharmacy Association","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,2]]},"abstract":"<jats:sec id=\"st1\">\n<jats:title>OBJECTIVE<\/jats:title>\n<jats:p>To review pediatric data on vancomycin exposure threshold against methicillin-resistant <jats:italic>Staphylococcus aureus<\/jats:italic> (MRSA) and coagulase-negative staphylococci (MR-CoNS).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st2\">\n<jats:title>METHODS<\/jats:title>\n<jats:p>A systematic review was conducted through July 2023. Publications in English that explored vancomycin effectiveness threshold against MRSA, CoNS, or <jats:italic>S aureus<\/jats:italic> in pediatrics were eligible. Effectiveness examined included clinical improvement, microbiologic sterilization, recurrence, and mortality, as defined by each individual study.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st3\">\n<jats:title>RESULTS<\/jats:title>\n<jats:p>Twelve studies were eligible. One on MRSA bacteremia (MRSA-B) identified an area under the curve to minimum inhibitory concentration ratio (AUC:MIC) of 300 mg \u00d7 hr\/L associated with rapid bacteremia clearance. Two on CoNS bacteremia (percentage of MR-CoNS unreported) demonstrated an AUC of 300 mg x hr\/L regardless of MIC and an AUC:MIC of 280 mg \u00d7 hr\/L for bacteriologic cure, respectively; and one on <jats:italic>S aureus<\/jats:italic> bacteremia (25.5% MRSA) found an AUC:MIC of 400 mg \u00d7 hr\/L for clinical improvement.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"st4\">\n<jats:title>CONCLUSIONS<\/jats:title>\n<jats:p>There is overall limited pediatric data, and the observed AUC:MIC thresholds should be interpreted as hypothesis generating only. Further, the effectiveness outcome could be refined in future research by using time to bacteremia clearance only, as odds of complications increase with each additional day of MRSA-B, whereas the definition of recurrence is not standardized, and mortality is low. Additionally, extrapolating AUC:MIC for MRSA to CoNS is beyond the stated usage of current guidelines. To achieve an AUC:MIC ratio against CoNS with a MIC of &gt;1 mg\/L would require higher AUC with potential nephrotoxicity. More data on AUC (regardless of MIC) for MR-CoNS bacteremia are needed.<\/jats:p>\n<\/jats:sec>","DOI":"10.5863\/1551-6776-30.1.52","type":"journal-article","created":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T14:25:25Z","timestamp":1745245525000},"page":"52-64","source":"Crossref","is-referenced-by-count":0,"title":["Vancomycin Area Under the Curve to Minimum Inhibitory Concentration Ratio for Treatment Effectiveness in Pediatric and Neonatal Staphylococcal Infections: A Systematic Review"],"prefix":"10.5863","volume":"30","author":[{"given":"Rou-Yee","family":"Chenhsu","sequence":"first","affiliation":[{"name":"Department of Pharmacy (R-YC, BAH, HT, MAD), Department of Pediatrics, Division of Infectious Diseases (RC, NAN), UC Davis Children\u2019s Hospital, Sacramento, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brent A.","family":"Hall","sequence":"additional","affiliation":[{"name":"Department of Pharmacy (R-YC, BAH, HT, MAD), Department of Pediatrics, Division of Infectious Diseases (RC, NAN), UC Davis Children\u2019s Hospital, Sacramento, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Heidi","family":"Tran","sequence":"additional","affiliation":[{"name":"Department of Pharmacy (R-YC, BAH, HT, MAD), Department of Pediatrics, Division of Infectious Diseases (RC, NAN), UC Davis Children\u2019s Hospital, Sacramento, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica A.","family":"Donnelley","sequence":"additional","affiliation":[{"name":"Department of Pharmacy (R-YC, BAH, HT, MAD), Department of Pediatrics, Division of Infectious Diseases (RC, NAN), UC Davis Children\u2019s Hospital, Sacramento, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ritu","family":"Cheema","sequence":"additional","affiliation":[{"name":"Department of Pharmacy (R-YC, BAH, HT, MAD), Department of Pediatrics, Division of Infectious Diseases (RC, NAN), UC Davis Children\u2019s Hospital, Sacramento, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Natasha A.","family":"Nakra","sequence":"additional","affiliation":[{"name":"Department of Pharmacy (R-YC, BAH, HT, MAD), Department of Pediatrics, Division of Infectious Diseases (RC, NAN), UC Davis Children\u2019s Hospital, Sacramento, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"3883","reference":[{"issue":"(suppl 1)","key":"i2331-348X-30-1-52-b01","series-title":"Clin Infect Dis","first-page":"S35","article-title":"The pharmacokinetic and pharmacodynamic properties of vancomycin","volume":"42","author":"Rybak","year":"2006","unstructured":"Rybak MJ. The pharmacokinetic and pharmacodynamic properties of vancomycin. Clin Infect Dis. 2006;42(suppl 1):S35\u2013S39."},{"issue":"(1)","key":"i2331-348X-30-1-52-b02","series-title":"BMC Infect Dis","first-page":"534","article-title":"Relationship between day 1 and day 2 vancomycin area under the curve values and emergence of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) by Etest\u00ae macromethod among patients with MRSA bloodstream infections: a pilot study","volume":"17","author":"Martirosov","year":"2017","unstructured":"Martirosov DM, Bidell MR, Pai MP, et al. Relationship between day 1 and day 2 vancomycin area under the curve values and emergence of heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) by Etest\u00ae macromethod among patients with MRSA bloodstream infections: a pilot study. BMC Infect Dis. 2017;17(1):534."},{"issue":"(9)","key":"i2331-348X-30-1-52-b03","series-title":"Pharmacotherapy","first-page":"741","article-title":"Vancomycin area under the curve versus trough only guided dosing and the risk of acute kidney injury: systematic review and meta-analysis","volume":"42","author":"Abdelmessih","year":"2022","unstructured":"Abdelmessih E, Patel N, Vekaria J, et al. Vancomycin area under the curve versus trough only guided dosing and the risk of acute kidney injury: systematic review and meta-analysis. Pharmacotherapy. 2022;42(9):741\u2013753."},{"issue":"(6)","key":"i2331-348X-30-1-52-b04","series-title":"Clin Infect Dis","first-page":"1361","article-title":"Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists","volume":"71","author":"Rybak","year":"2020","unstructured":"Rybak MJ, Le J, Lodise TP, et al. Therapeutic monitoring of vancomycin for serious methicillin-resistant Staphylococcus aureus infections: a revised consensus guideline and review by the American Society of Health-system Pharmacists, the Infectious Diseases Society of America, the Pediatric Infectious Diseases Society, and the Society of Infectious Diseases Pharmacists. Clin Infect Dis. 2020;71(6):1361\u20131364."},{"issue":"(7)","key":"i2331-348X-30-1-52-b05","series-title":"Pediatr Infect Dis J","first-page":"654","article-title":"Nephrotoxicity with vancomycin in the pediatric population: a systematic review and meta-analysis","volume":"37","author":"Fiorito","year":"2018","unstructured":"Fiorito TM, Luther MK, Dennehy PH, et al. Nephrotoxicity with vancomycin in the pediatric population: a systematic review and meta-analysis. Pediatr Infect Dis J. 2018;37(7):654\u2013661."},{"key":"i2331-348X-30-1-52-b06","series-title":"Adv Drug Deliv Rev","first-page":"50","article-title":"Innovative approaches to optimizing the delivery of vancomycin in individual patients","volume":"77","author":"Pai","year":"2014","unstructured":"Pai MP, Neely M, Rodvold KA, Lodise TP. Innovative approaches to optimizing the delivery of vancomycin in individual patients. Adv Drug Deliv Rev. 2014;77:50\u201357."},{"issue":"(11)","key":"i2331-348X-30-1-52-b07","series-title":"Hosp Pediatr","first-page":"e289","article-title":"A multicenter retrospective study of vancomycin dosing by weight measures in children","volume":"11","author":"Khare","year":"2021","unstructured":"Khare M, Haag MB, Kneese G, et al. A multicenter retrospective study of vancomycin dosing by weight measures in children. Hosp Pediatr. 2021;11(11):e289\u2013e296."},{"issue":"(4)","key":"i2331-348X-30-1-52-b08","series-title":"Clin Microbiol Infect","first-page":"436","article-title":"Vancomycin area under the curve to minimum inhibitory concentration ratio predicting clinical outcome: a systematic review and meta-analysis with pooled sensitivity and specificity","volume":"26","author":"Dalton","year":"2020","unstructured":"Dalton BR, Rajakumar I, Langevin A, et al. Vancomycin area under the curve to minimum inhibitory concentration ratio predicting clinical outcome: a systematic review and meta-analysis with pooled sensitivity and specificity. Clin Microbiol Infect. 2020;26(4):436\u2013446."},{"issue":"(9)","key":"i2331-348X-30-1-52-b09","series-title":"J Antimicrob Chemother","first-page":"2237","article-title":"AUCs and 123s: a critical appraisal of vancomycin therapeutic drug monitoring in paediatrics","volume":"76","author":"Jorgensen","year":"2021","unstructured":"Jorgensen SCJ, Dersch-Mills D, Timberlake K, et al. AUCs and 123s: a critical appraisal of vancomycin therapeutic drug monitoring in paediatrics. J Antimicrob Chemother. 2021;76(9):2237\u20132251."},{"key":"i2331-348X-30-1-52-b10","series-title":"BMJ","first-page":"n160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","unstructured":"Page MJ, Moher D, Bossuyt PM, et al. PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews. BMJ. 2021;372:n160."},{"key":"i2331-348X-30-1-52-b11","series-title":"BMC Med Inform Decis Mak","first-page":"16","article-title":"Utilization of the PICO framework to improve searching PubMed for clinical questions","volume":"7","author":"Schardt","year":"2007","unstructured":"Schardt C, Adams MB, Owens T, et al. Utilization of the PICO framework to improve searching PubMed for clinical questions. BMC Med Inform Decis Mak. 2007;7:16."},{"issue":"(2)","key":"i2331-348X-30-1-52-b12","series-title":"Clin Infect Dis","first-page":"193","article-title":"Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia","volume":"46","author":"Soriano","year":"2008","unstructured":"Soriano A, Marco F, Mart\u00ednez JA, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008;46(2):193\u2013200."},{"issue":"(3)","key":"i2331-348X-30-1-52-b13","series-title":"J Pediatr Pharmacol Ther","first-page":"218","article-title":"Predictors of adverse outcomes in children with Staphylococcus aureus bacteremia","volume":"22","author":"Kumarachandran","year":"2017","unstructured":"Kumarachandran G, Johnson JK, Shirley DA, et al. Predictors of adverse outcomes in children with Staphylococcus aureus bacteremia. J Pediatr Pharmacol Ther. 2017;22(3):218\u2013226."},{"key":"i2331-348X-30-1-52-b14","article-title":"The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute","author":"Wells","year":"2014","unstructured":"Wells G, Shea B, O\u2019Connell D, et al. The Newcastle-Ottawa scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Ottawa Hospital Research Institute. 2014. Accessed October 30, 2023. http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/ oxford.asp"},{"issue":"(8)","key":"i2331-348X-30-1-52-b15","series-title":"Clin Microbiol Infect","first-page":"1076","article-title":"Staphylococcus aureus bacteraemia mortality: a systematic review and meta-analysis","volume":"28","author":"Bai","year":"2022","unstructured":"Bai AD, Lo CKL, Komorowski AS, et al. Staphylococcus aureus bacteraemia mortality: a systematic review and meta-analysis. Clin Microbiol Infect. 2022;28(8):1076\u20131084."},{"issue":"(5)","key":"i2331-348X-30-1-52-b16","series-title":"Ther Drug Monit","first-page":"619","article-title":"Evaluation of target attainment of vancomycin area under the curve in children with methicillin-resistant Staphylococcus aureus bacteremia","volume":"37","author":"Hahn","year":"2015","unstructured":"Hahn A, Frenck RW Jr, Allen-Staat M, et al. Evaluation of target attainment of vancomycin area under the curve in children with methicillin-resistant Staphylococcus aureus bacteremia. Ther Drug Monit. 2015;37(5):619\u2013625."},{"issue":"(suppl 1)","key":"i2331-348X-30-1-52-b17","series-title":"Open Forum Infect Dis","first-page":"S293","article-title":"Evaluation of early achievement of an AUC\/MIC of >400 for vancomycin in children with methicillin-resistant Staphylococcus aureus bacteremia","volume":"4","author":"Murai","year":"2017","unstructured":"Murai T, Higuchi H, Suwa J, et al. Evaluation of early achievement of an AUC\/MIC of >400 for vancomycin in children with methicillin-resistant Staphylococcus aureus bacteremia. Open Forum Infect Dis. 2017;4(suppl 1):S293\u2013S294."},{"issue":"(1)","key":"i2331-348X-30-1-52-b18","series-title":"J Pediatr Pharmacol Ther","first-page":"41","article-title":"Vancomycin AUC\/MIC and corresponding troughs in a pediatric population","volume":"22","author":"Kishk","year":"2017","unstructured":"Kishk OA, Lardieri AB, Heil EL, et al. Vancomycin AUC\/MIC and corresponding troughs in a pediatric population. J Pediatr Pharmacol Ther. 2017;22(1):41\u201347."},{"issue":"(5)","key":"i2331-348X-30-1-52-b19","series-title":"Minerva Pediatr (Torino)","first-page":"525","article-title":"Influence of pharmacokinetic\/pharmacodynamic ratio on vancomycin treatment response in pediatric patients with Staphylococcus aureus bacteremia","volume":"74","author":"Ruiz","year":"2022","unstructured":"Ruiz J, Garc\u00eda-Robles A, Marqu\u00e9s MR, et al. Influence of pharmacokinetic\/pharmacodynamic ratio on vancomycin treatment response in pediatric patients with Staphylococcus aureus bacteremia. Minerva Pediatr (Torino). 2022;74(5):525\u2013529."},{"issue":"(4)","key":"i2331-348X-30-1-52-b20","series-title":"J Pediatr Pharmacol Ther","first-page":"312319","article-title":"Vancomycin treatment failure in children with methicillin-resistant Staphylococcus aureus bacteremia","volume":"24","author":"Regen","year":"2019","unstructured":"Regen RB, Schuman SS, Chhim RF, et al. Vancomycin treatment failure in children with methicillin-resistant Staphylococcus aureus bacteremia. J Pediatr Pharmacol Ther. 2019;24(4):312319."},{"issue":"(1)","key":"i2331-348X-30-1-52-b21","series-title":"BMC Pediatr","first-page":"206","article-title":"Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target?","volume":"16","author":"Padari","year":"2016","unstructured":"Padari H, Oselin K, Tasa T, et al. Coagulase negative staphylococcal sepsis in neonates: do we need to adapt vancomycin dose or target? BMC Pediatr. 2016;16(1):206."},{"issue":"(4)","key":"i2331-348X-30-1-52-b22","series-title":"PLoS One","first-page":"e0247714","article-title":"Impact of initial vancomycin pharmacokinetic\/pharmacodynamic parameters on the clinical and microbiological outcomes of methicillin-resistant Staphylococcus aureus bacteremia in children","volume":"16","author":"Yoo","year":"2021","unstructured":"Yoo R, So H, Seo E, et al. Impact of initial vancomycin pharmacokinetic\/pharmacodynamic parameters on the clinical and microbiological outcomes of methicillin-resistant Staphylococcus aureus bacteremia in children. PLoS One. 2021;16(4):e0247714."},{"issue":"(3)","key":"i2331-348X-30-1-52-b23","series-title":"J Pediatric Infect Dis Soc","first-page":"e103","article-title":"Association of vancomycin trough concentration with response to treatment for acute pulmonary exacerbation of cystic fibrosis","volume":"6","author":"Fusco","year":"2017","unstructured":"Fusco NM, Francisconi R, Meaney CJ, et al. Association of vancomycin trough concentration with response to treatment for acute pulmonary exacerbation of cystic fibrosis. J Pediatric Infect Dis Soc. 2017;6(3):e103\u2013e108."},{"issue":"(3)","key":"i2331-348X-30-1-52-b24","series-title":"Pediatr Neonatol","first-page":"247","article-title":"Optimal exposure targets for vancomycin in the treatment of neonatal coagulase-negative Staphylococcus infection: a retrospective study based on electronic medical records","volume":"63","author":"Chen","year":"2022","unstructured":"Chen Q, Wan J, Shen W, et al. Optimal exposure targets for vancomycin in the treatment of neonatal coagulase-negative Staphylococcus infection: a retrospective study based on electronic medical records. Pediatr Neonatol. 2022;63(3):247\u2013254."},{"issue":"(3)","key":"i2331-348X-30-1-52-b25","series-title":"J Antimicrob Chemother","first-page":"704","article-title":"Identifying a therapeutic target for vancomycin against Staphylococci in young infants","volume":"77","author":"Gwee","year":"2022","unstructured":"Gwee A, Duffull SB, Daley AJ, et al. Identifying a therapeutic target for vancomycin against Staphylococci in young infants. J Antimicrob Chemother. 2022;77(3):704\u2013710."},{"issue":"(suppl 1)","key":"i2331-348X-30-1-52-b26","series-title":"Open Forum Infect Dis","first-page":"S4","article-title":"Impact of vancomycin serum trough-concentrations and vancomycin AUC\/MIC on vancomycin response, in-hospital outcomes and acute kidney injury in pediatric Staphylococcus aureus pneumonia","volume":"4","author":"McNeil","year":"2017","unstructured":"McNeil J, Rosas L, Hulten K, et al. Impact of vancomycin serum trough-concentrations and vancomycin AUC\/MIC on vancomycin response, in-hospital outcomes and acute kidney injury in pediatric Staphylococcus aureus pneumonia. Open Forum Infect Dis. 2017;4(suppl 1):S4."},{"issue":"(1)","key":"i2331-348X-30-1-52-b27","series-title":"J Perinatol","first-page":"97","article-title":"Vancomycin drug monitoring in infants with CoNS sepsis-target attainment, microbiological response and nephrotoxicity","volume":"40","author":"Viel-Th\u00e9riault","year":"2020","unstructured":"Viel-Th\u00e9riault I, Martin B, Thompson-Desormeaux F, et al. Vancomycin drug monitoring in infants with CoNS sepsis-target attainment, microbiological response and nephrotoxicity. J Perinatol. 2020;40(1):97\u2013104."},{"issue":"(8)","key":"i2331-348X-30-1-52-b28","series-title":"Pediatr Infect Dis J","first-page":"667","article-title":"Influence of malignancy on the pharmacokinetics of vancomycin in infants and children","volume":"14","author":"Chang","year":"1995","unstructured":"Chang D. Influence of malignancy on the pharmacokinetics of vancomycin in infants and children. Pediatr Infect Dis J. 1995;14(8):667\u201373."},{"issue":"(4)","key":"i2331-348X-30-1-52-b29","series-title":"Pediatr Infect Dis J","first-page":"e155\u201363","article-title":"Improved vancomycin dosing in children using area under the curve exposure","volume":"32","author":"Le","year":"2013","unstructured":"Le J, Bradley JS, Murray W, et al. Improved vancomycin dosing in children using area under the curve exposure. Pediatr Infect Dis J. 2013 Apr;32(4):e155\u201363."},{"issue":"(9)","key":"i2331-348X-30-1-52-b30","series-title":"Antimicrob Agents Chemother","first-page":"4277","article-title":"Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding","volume":"55","author":"Butterfield","year":"2011","unstructured":"Butterfield JM, Patel N, Pai MP, et al. Refining vancomycin protein binding estimates: identification of clinical factors that influence protein binding. Antimicrob Agents Chemother. 2011;55(9):4277\u20134282."},{"issue":"(3)","key":"i2331-348X-30-1-52-b31","series-title":"J Antimicrob Chemother","first-page":"801","article-title":"Impact of vancomycin protein binding on target attainment in critically ill children: back to the drawing board?","volume":"72","author":"De Cock","year":"2017","unstructured":"De Cock PA, Desmet S, De Jaeger A, et al. Impact of vancomycin protein binding on target attainment in critically ill children: back to the drawing board? J Antimicrob Chemother. 2017;72(3):801\u2013804."},{"issue":"(8)","key":"i2331-348X-30-1-52-b32","series-title":"Eur J Clin Microbiol Infect Dis","first-page":"1503","article-title":"Factors impacting unbound vancomycin concentrations in neonates and young infants","volume":"37","author":"Smits","year":"2018","unstructured":"Smits A, Pauwels S, Oyaert M, et al. Factors impacting unbound vancomycin concentrations in neonates and young infants. Eur J Clin Microbiol Infect Dis. 2018;37(8):1503\u20131510."},{"issue":"(5)","key":"i2331-348X-30-1-52-b33","series-title":"Clin Infect Dis","first-page":"666","article-title":"Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough?","volume":"59","author":"Lodise","year":"2014","unstructured":"Lodise TP, Drusano GL, Zasowski E, et al. Vancomycin exposure in patients with methicillin-resistant Staphylococcus aureus bloodstream infections: how much is enough? Clin Infect Dis. 2014;59(5):666\u2013675."},{"issue":"(8)","key":"i2331-348X-30-1-52-b34","series-title":"Clin Infect Dis","first-page":"1536","article-title":"The emperor\u2019s new clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE)","volume":"70","author":"Lodise","year":"2020","unstructured":"Lodise TP, Rosenkranz SL, Finnemeyer M, et al. The emperor\u2019s new clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE). Clin Infect Dis. 2020;70(8):1536\u20131545."},{"issue":"(2)","key":"i2331-348X-30-1-52-b35","series-title":"Int J Antimicrob Agents","first-page":"179","article-title":"Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia","volume":"43","author":"Jung","year":"2014","unstructured":"Jung Y, Song KH, Cho Je, et al. Area under the concentration-time curve to minimum inhibitory concentration ratio as a predictor of vancomycin treatment outcome in methicillin-resistant Staphylococcus aureus bacteraemia. Int J Antimicrob Agents. 2014;43(2):179\u2013183."},{"issue":"(12)","key":"i2331-348X-30-1-52-b36","series-title":"Clin Microbiol Infect","first-page":"O1098","article-title":"Impact of source of infection and vancomycin AUC0-24\/MICBMD targets on treatment failure in patients with methicillin-resistant Staphylococcus aureus bacteraemia","volume":"20","author":"Ghosh","year":"2014","unstructured":"Ghosh N, Chavada R, Maley M, van Hal SJ. Impact of source of infection and vancomycin AUC0-24\/MICBMD targets on treatment failure in patients with methicillin-resistant Staphylococcus aureus bacteraemia. Clin Microbiol Infect. 2014;20(12):O1098\u2013O1105."},{"issue":"(2)","key":"i2331-348X-30-1-52-b37","series-title":"Clin Infect Dis","first-page":"173","article-title":"Combination of vancomycin and \u03b2-lactam therapy for methicillin-resistant Staphylococcus aureus bacteremia: a pilot multicenter randomized controlled trial","volume":"62","author":"Davis","year":"2016","unstructured":"Davis JS, Sud A, O\u2019Sullivan MVN, et al; Combination Antibiotics for MEthicillin Resistant Staphylococcus aureus (CAMERA) Study Group. Combination of vancomycin and \u03b2-lactam therapy for methicillin-resistant Staphylococcus aureus bacteremia: a pilot multicenter randomized controlled trial. Clin Infect Dis. 2016;62(2):173\u2013180."},{"issue":"(6)","key":"i2331-348X-30-1-52-b38","series-title":"Int J Antimicrob Agents","first-page":"805","article-title":"Implementation of a two-point pharmacokinetic AUC-based vancomycin therapeutic drug monitoring approach in patients with methicillin-resistant Staphylococcus aureus bacteraemia","volume":"52","author":"Mogle","year":"2018","unstructured":"Mogle BT, Steele JM, Seabury RW, et al. Implementation of a two-point pharmacokinetic AUC-based vancomycin therapeutic drug monitoring approach in patients with methicillin-resistant Staphylococcus aureus bacteraemia. Int J Antimicrob Agents. 2018;52(6):805\u2013810."},{"issue":"(suppl 1)","key":"i2331-348X-30-1-52-b39","series-title":"Clin Infect Dis","first-page":"S68","article-title":"Comparative effectiveness of switching to daptomycin versus remaining on vancomycin among patients with methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections","volume":"72","author":"Schweizer","year":"2021","unstructured":"Schweizer ML, Richardson K, Vaughan Sarrazin MS, et al. Comparative effectiveness of switching to daptomycin versus remaining on vancomycin among patients with methicillin-resistant Staphylococcus aureus (MRSA) bloodstream infections. Clin Infect Dis. 2021;72(suppl 1):S68\u2013S73."},{"issue":"(10)","key":"i2331-348X-30-1-52-b40","series-title":"Antimicrob Agents Chemother","first-page":"5841","article-title":"Daptomycin improves outcomes regardless of vancomycin mic in a propensity-matched analysis of methicillin-resistant Staphylococcus aureus bloodstream infections","volume":"60","author":"Claeys","year":"2016","unstructured":"Claeys KC, Zasowski EJ, Casapao AM, et al. Daptomycin improves outcomes regardless of vancomycin mic in a propensity-matched analysis of methicillin-resistant Staphylococcus aureus bloodstream infections. Antimicrob Agents Chemother. 2016;60(10):5841\u20135848."},{"issue":"(4)","key":"i2331-348X-30-1-52-b41","series-title":"Diagn Microbiol Infect Dis","first-page":"408","article-title":"Relationships between vancomycin minimum inhibitory concentration, dosing strategies, and outcomes in methicillin-resistant Staphylococcus aureus bacteremia","volume":"71","author":"Clemens","year":"2011","unstructured":"Clemens EC, Chan JD, Lynch JB, Dellit TH. Relationships between vancomycin minimum inhibitory concentration, dosing strategies, and outcomes in methicillin-resistant Staphylococcus aureus bacteremia. Diagn Microbiol Infect Dis. 2011;71(4):408\u2013414."},{"issue":"(5)","key":"i2331-348X-30-1-52-b42","series-title":"Antimicrob Agents Chemother","first-page":"3070","article-title":"Vancomycin 24-hour area under the curve\/minimum bactericidal concentration ratio as a novel predictor of mortality in methicillin-resistant Staphylococcus aureus bacteremia","volume":"60","author":"Britt","year":"2016","unstructured":"Britt NS, Patel N, Horvat RT, Steed ME. Vancomycin 24-hour area under the curve\/minimum bactericidal concentration ratio as a novel predictor of mortality in methicillin-resistant Staphylococcus aureus bacteremia. Antimicrob Agents Chemother. 2016;60(5):3070\u20133075."},{"issue":"(6)","key":"i2331-348X-30-1-52-b43","series-title":"Int J Antimicrob Agents","first-page":"689","article-title":"Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia","volume":"46","author":"Song","year":"2015","unstructured":"Song KH, Kim HB, Kim HS, et al. Impact of area under the concentration-time curve to minimum inhibitory concentration ratio on vancomycin treatment outcomes in methicillin-resistant Staphylococcus aureus bacteraemia. Int J Antimicrob Agents. 2015;46(6):689\u2013695."},{"issue":"(8)","key":"i2331-348X-30-1-52-b44","series-title":"Clin Infect Dis","first-page":"975","article-title":"Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets","volume":"52","author":"Kullar","year":"2011","unstructured":"Kullar R, Davis SL, Levine DP, Rybak MJ. Impact of vancomycin exposure on outcomes in patients with methicillin-resistant Staphylococcus aureus bacteremia: support for consensus guidelines suggested targets. Clin Infect Dis. 2011;52(8):975\u2013981."},{"issue":"(12)","key":"i2331-348X-30-1-52-b45","series-title":"Clin Infect Dis","first-page":"2112","article-title":"Methicillin-susceptible and methicillin-resistant Staphylococcus aureus bacteremia: nationwide estimates of 30-day readmission, in-hospital mortality, length of stay, and cost in the United States","volume":"69","author":"Inagaki","year":"2019","unstructured":"Inagaki K, Lucar J, Blackshear C, Hobbs CV. Methicillin-susceptible and methicillin-resistant Staphylococcus aureus bacteremia: nationwide estimates of 30-day readmission, in-hospital mortality, length of stay, and cost in the United States. Clin Infect Dis. 2019;69(12):2112\u20132118."},{"issue":"(3)","key":"i2331-348X-30-1-52-b46","series-title":"Eur J Clin Microbiol Infect Dis","first-page":"295","article-title":"Factors influencing the clinical outcome of methicillin-resistant Staphylococcus aureus bacteraemia","volume":"31","author":"Albur","year":"2012","unstructured":"Albur MS, Bowker K, Weir I, MacGowan A. Factors influencing the clinical outcome of methicillin-resistant Staphylococcus aureus bacteraemia. Eur J Clin Microbiol Infect Dis. 2012;31(3):295\u2013301."},{"issue":"(8)","key":"i2331-348X-30-1-52-b47","series-title":"Clin Infect Dis","first-page":"1666","article-title":"Reduced mortality of Staphylococcus aureus bacteremia in a retrospective cohort study of 2139 patients: 2007-2015","volume":"70","author":"Austin","year":"2020","unstructured":"Austin ED, Sullivan SS, Macesic N, et al. Reduced mortality of Staphylococcus aureus bacteremia in a retrospective cohort study of 2139 patients: 2007-2015. Clin Infect Dis. 2020;70(8):1666\u20131674."},{"issue":"(6)","key":"i2331-348X-30-1-52-b48","series-title":"Pediatrics","first-page":"e20170183","article-title":"Epidemiology of methicillin-resistant Staphylococcus aureus bacteremia in children","volume":"139","author":"Hamdy","year":"2017","unstructured":"Hamdy RF, Hsu AJ, Stockmann C, et al. Epidemiology of methicillin-resistant Staphylococcus aureus bacteremia in children. Pediatrics. 2017;139(6):e20170183."},{"issue":"(10)","key":"i2331-348X-30-1-52-b49","series-title":"JAMA Pediatr","first-page":"979","article-title":"Epidemiology and mortality of Staphylococcus aureus bacteremia in Australian and New Zealand children","volume":"170","author":"McMullan","year":"2016","unstructured":"McMullan BJ, Bowen A, Blyth CC, et al. Epidemiology and mortality of Staphylococcus aureus bacteremia in Australian and New Zealand children. JAMA Pediatr. 2016;170(10):979\u2013986."},{"issue":"(4)","key":"i2331-348X-30-1-52-b50","series-title":"Clin Infect Dis","first-page":"566","article-title":"Defining the breakpoint duration of Staphylococcus aureus bacteremia predictive of poor outcomes","volume":"70","author":"Minejima","year":"2020","unstructured":"Minejima E, Mai N, Bui N, et al. Defining the breakpoint duration of Staphylococcus aureus bacteremia predictive of poor outcomes. Clin Infect Dis. 2020;70(4):566\u2013573."},{"issue":"(4)","key":"i2331-348X-30-1-52-b51","series-title":"Clin Infect Dis","first-page":"604","article-title":"Pediatric Staphylococcus aureus bacteremia: clinical spectrum and predictors of poor outcome","volume":"74","author":"Campbell","year":"2022","unstructured":"Campbell AJ, Al Yazidi LS, Phuong LK, et al. Pediatric Staphylococcus aureus bacteremia: clinical spectrum and predictors of poor outcome. Clin Infect Dis. 2022;74(4):604\u2013613."},{"issue":"(12)","key":"i2331-348X-30-1-52-b52","series-title":"JAMA Pediatr","first-page":"1105","article-title":"Burden of invasive Staphylococcus aureus infections in hospitalized infants","volume":"169","author":"Ericson","year":"2015","unstructured":"Ericson JE, Popoola VO, Smith PB, et al. Burden of invasive Staphylococcus aureus infections in hospitalized infants. JAMA Pediatr. 2015;169(12):1105\u20131111."},{"issue":"(4)","key":"i2331-348X-30-1-52-b53","series-title":"J Pediatric Infect Dis Soc","first-page":"338","article-title":"Association between vancomycin trough concentrations and duration of methicillin-resistant Staphylococcus aureus \u00adbacteremia in children","volume":"7","author":"Hsu","year":"2018","unstructured":"Hsu AJ, Hamdy RF, Huang Y, et al. Association between vancomycin trough concentrations and duration of methicillin-resistant Staphylococcus aureus \u00adbacteremia in children. J Pediatric Infect Dis Soc. 2018;7(4):338\u2013341."},{"issue":"(7)","key":"i2331-348X-30-1-52-b54","series-title":"Infect Control Hosp Epidemiol","first-page":"679","article-title":"Coagulase-negative staphylococcal infections in the neonatal intensive care unit","volume":"32","author":"Jean-Baptiste","year":"2011","unstructured":"Jean-Baptiste N, Benjamin DK Jr, Cohen-Wolkowiez M, et al. Coagulase-negative staphylococcal infections in the neonatal intensive care unit. Infect Control Hosp Epidemiol. 2011;32(7):679\u2013686."},{"issue":"(4)","key":"i2331-348X-30-1-52-b55","series-title":"Pediatr Infect Dis J","first-page":"371","article-title":"Antibacterial resistance leadership group: no survival benefit with empirical vancomycin therapy for coagulase-negative staphylococcal bloodstream infections in infants","volume":"34","author":"Ericson","year":"2015","unstructured":"Ericson JE, Thaden J, Cross HR, et al. Antibacterial resistance leadership group: no survival benefit with empirical vancomycin therapy for coagulase-negative staphylococcal bloodstream infections in infants. Pediatr Infect Dis J. 2015;34(4):371\u2013375."},{"issue":"(2)","key":"i2331-348X-30-1-52-b56","series-title":"Diagn Microbiol Infect Dis","first-page":"115108","article-title":"Frequency and antimicrobial susceptibility of bacteria causing bloodstream infections in pediatric patients from United States (US) medical centers (2014-2018): therapeutic options for multidrug-resistant bacteria","volume":"98","author":"Sader","year":"2020","unstructured":"Sader HS, Castanheira M, Streit JM, et al. Frequency and antimicrobial susceptibility of bacteria causing bloodstream infections in pediatric patients from United States (US) medical centers (2014-2018): therapeutic options for multidrug-resistant bacteria. Diagn Microbiol Infect Dis. 2020;98(2):115108."},{"key":"i2331-348X-30-1-52-b57","unstructured":"The European Committee on Antimicrobial Susceptibility Testing. Antimicrobial wild type distributions of microorganisms. Accessed October 30, 2023. https:\/\/mic.eucast.org\/search\/?search%5Bmethod%5D=mic&search%5Bantibiotic%5D=200&search%5Bspecies%5D=-1&search%5Bdisk_content%5D=-1&search%5Blimit%5D=50"},{"issue":"(12)","key":"i2331-348X-30-1-52-b58","series-title":"J Clin Microbiol","first-page":"4652","article-title":"for methicillin-resistant coagulase-negative Staphylococcus isolates: evaluation of the broth microdilution and Etest methods","volume":"48","author":"Paiva","year":"2010","unstructured":"Paiva RM, Mombach Pinheiro Machado AB, Zavascki AP, Barth AL. Vancomycin MIC for methicillin-resistant coagulase-negative Staphylococcus isolates: evaluation of the broth microdilution and Etest methods. J Clin Microbiol. 2010;48(12):4652\u20134654."}],"container-title":["The Journal of Pediatric Pharmacology and Therapeutics"],"original-title":[],"link":[{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/30\/1\/article-p52.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/30\/1\/article-p52.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jppt.kglmeridian.com\/downloadpdf\/journals\/jppt\/30\/1\/article-p52.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,21]],"date-time":"2025-04-21T14:25:25Z","timestamp":1745245525000},"score":1,"resource":{"primary":{"URL":"https:\/\/jppt.kglmeridian.com\/view\/journals\/jppt\/30\/1\/article-p52.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":58,"journal-issue":{"issue":"1"},"URL":"https:\/\/doi.org\/10.5863\/1551-6776-30.1.52","relation":{},"ISSN":["2331-348X","1551-6776"],"issn-type":[{"type":"electronic","value":"2331-348X"},{"type":"print","value":"1551-6776"}],"subject":[],"published":{"date-parts":[[2025,2]]}}}